


Memorial Sloan Kettering ASCO Meeting Abstracts 2015

The American Society of Clinical Oncology meeting this year had close to 6,000 abstracts submitted for review, with 4,882 abstracts published in conjunction with this conference. Of these abstracts 2,392 were presented onsite during the poster discussion, oral abstract, and poster sessions.

Memorial Sloan Kettering contributed 296 abstracts which represents an increase of approximately 15% from last year's total abstract count. Also last year, there were 7 MSK authors that published 10 or more abstracts. This year there were 12 MSK authors that published 10 or more abstracts: C.A. Hudis (18), M.F. Berger (15), D.M. Hyman (15), M.G. Kris (15), R.J. Motzer (13), M.E. Arcila (12), L.B. Saltz (11), M. Ladanyi (10), H.I. Scher (10), D.B. Solit (10), M.H. Voss (10), and J.D. Wolchok (10). The top three categories (as determined by ASCO) were Genitourinary (Nonprostate) Cancer (26), Gastrointestinal (Noncolorectal) Cancer (21), and Lung Cancer-Non-Small Cell Metastatic (21). The abstracts include three on the historic IBM Watson Oncology application being implemented at MSK.



1. Abdel-Fatah TMA, Liu D, Agarwal D, Russell R, Rueda OM, Moseley PM, Green AR, Mukherjee A, Reis-Filho J, Caldas C, Ellis IO, Ball G, Chan SYT. Mechanistic and clinical analysis of sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in breast cancer (BC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1040.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1040

2. Abernethy AP, Postow MA, Chesney JA, Grossmann KF, Taylor F, Coon C, Gilloteau I, Dastani H, Gagnier P, Robert C. Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9029.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9029

3. Abida W, Curtis KR, Taylor BS, Arcila ME, Brennan R, Danila DC, Rathkopf DE, Morris MJ, Slovin SF, Solit DB, Hyman DM, Gopalan A, Berger MF, Schultz N, Scher HI. Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5062.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5062

4. Abou-Alfa GK, Capanu M, Do RKG, Hollywood E, Ly M, Chou JF, Lee JK, Connell LC, Wan PJ, Bradley M, Harding JJ, Saltz L. First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15147.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15147

5. Abou-Alfa GK, Mayer RJ, Cosgrove D, Capanu M, Choti MA, Atreya CE, Ang C, Kelley RK, Do RKG, Gordan JD, Zhu AX, Ly M, Nolan P, Lubin L, Harding JJ, Saltz L, Venook AP. Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15149. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15149
6. Abu Zaid MI, Sesso HD, Fung C, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Moore MJ, Sahasrabudhe DM, Johnson E, Fossa S, Einhorn LH, Travis LB, The Platinum Study Group . Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9519. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9519
7. Aghajanian C, Filiaci VL, Dizon DS, Carlson J, Powell MA, Secord AA, Tewari KS, Bender D, O'Malley DM, Stuckey A, Rotmensch J, Levine DA, Lankes HA, Moore KN. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5500. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5500
8. Algazi AP, Muthukumar AH, O'Brien K, Lencioni A, Tsai KK, Kadafour M, Chapman PB, Daud A. Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9068. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9068
9. Ali A, Pendhakar S, Ali R, Chichra A, Pendharkar D. Incidence and survival of gallbladder cancer over three decades: A SEER database study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17651. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17651
10. Anand A, Minarik D, Kaboteh R, Lindgren Belal S, Reza M, Joseffson A, Edenbrandt L, Bjartell A. Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5044. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5044
11. Ang C, Miura JT, Gamblin TC, Millis SZ, Xiu J, Gatalica Z, Reddy SK, Yee NS. Molecular characterization of 350 hepatocellular carcinomas to identify biomarker aberrations with potential novel therapeutic options. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4086. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4086
12. Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, Ott PA, Pietanza MC, Horn L, Le DT, Morse M, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso J, Simon JS, Lin C, Eder JP. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7503. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7503
13. Arcila ME, Yu HA, Drilon AE, Riely GJ, Zehir A, Sadowska J, Hyman DM, Kris MG, Berger MF, Ladanyi M. Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e22160. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22160
14. Argolo, Daniel Fontes Santos De Teive E., Smyth LM, Iyengar NM, Patil S, Norton L, Baselga J, Hudis CA, Dang CT. Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 616. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/616

15. Armstrong GT, Yasui Y, Chen Y, Leisenring WM, Gibson TM, Mertens A, Stovall M, Hudson MM, Oeffinger KC, Bhatia S, Krull KR, Nathan PC, Neglia JP, Green DM, Robison LL. Reduction in late mortality among 5-year survivors of childhood cancer: A report from the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 June 22; 33(18_suppl): LBA2. http://meeting.ascopubs.org/cgi/content/abstract/33/18_suppl/LBA2
16. Atkinson TM, Hay JL, Doyle LA, Paucar D, Smith SC, Li Y, Carvajal RD. Relationship between physician-adjudicated adverse events (AE) and patient-reported health-related quality of life (HRQoL) in a phase II clinical trial of patients (pts) with metastatic uveal melanoma (UM). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9555. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9555
17. Atkinson TM, Satele DV, Sloan JA, Mehedint D, Lafky JM, Basch EM, Dueck AC. Comparison between clinician- and patient-reporting of baseline (BL) and post-BL symptomatic toxicities in cancer cooperative group clinical trials (NCCTG N0591 [alliance]). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9520. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9520
18. Atri M, Zhang Z, Dehdashti F, Lee S, Ali S, Koh W, Moore KN, Landrum LM, Kim J, DiSilvestro P, Eisenhauer EL, Schnell FM, Gold M. Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5585. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5585
19. Bajorin DF, Plimack ER, Siefker-Radtke AO, Choueiri TK, De Wit R, Sonpavde G, Gipson A, Brown H, Mai Y, Pang L, Perini RF, Bellmunt J. KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4572. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4572
20. Baker EH, Fruscione M, Cochran A, Millis SZ, Martinie JB, Swan RZ, Iannitti DA. Molecular profiling of pancreatic adenocarcinoma to identify targeted therapeutic options in patients who have undergone pancreaticoduodenectomy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15232. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15232
21. Bambury RM, Jordan E, Zabor EC, Bouvier N, Al-Ahmadie H, Boyd ME, Mullane SA, Cha EK, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Bajorin DF, Bellmunt J, Berger MF, Iyer G, Rosenberg JE. Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4532. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4532
22. Barrientos JC, Ghia P, Pagel J, Salles GA, Sharman JP, Stilgenbauer S, Gurtovaya O, Kim Y, Philip B, Zelenetz AD. Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-hodgkin's lymphoma (iNHL) in idelalisib (IDELA) trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8563. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8563
23. Baselga J, Cortes J, De Laurentiis M, Dieras V, Harbeck N, Im Y, Jacot W, Krop IE, Verma S, Wilson TR, Lin R, Schimmoller F, Hsu JY. SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS629. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS629
24. Basen-Engquist K, Huang HQ, Herzog TJ, Armstrong DK, Sabbatini P, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Coleman RL. Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG study--

analysis of patient reported outcomes (PRO) on chemotherapy randomization. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5525.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5525

25. Battaglin F, Stadler ZK, Cercek A, Yaeger RD, Segal NH, Varghese AM, Kemeny NE, Weiser MR, Garcia-Aguilar J, Shia J, Berger MF, Hechtman JF, Arcila ME, Solit DB, Saltz L. Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3565.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3565

26. Bauer TM, Chae YK, Patel S, D'Angelo SP, Blumenschein GR, Norton J, Pound C, Lanasa MC, Curti BD. A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS3093.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS3093

27. Baxi SS, Korenstein D. National comprehensive cancer network (NCCN) surveillance guidelines: Characteristics of post-treatment imaging recommendations in solid tumor malignancies. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17775.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17775

28. Baxi SS, Xiao H, Fury MG, Atoria CL, Dunn L, Salz T, Sherman EJ, Ho AL, Lee NY, Pfister DG. Employment and quality of life (QOL) in human papillomavirus-related (HPV+) oropharynx cancer treated with definitive chemoradiation (CTRT). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9587. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9587

29. Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Parli T, Mansbach HH, Bhattacharya S, Van Os S, Phung D, TOMBAL BF. Enzalutamide (ENZA) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5036.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5036

30. Bell-McGuinn KM, Brady WE, Schilder RJ, Fracasso PM, Moore KN, Walker JL, Duska LR, Mathews CA, Chen A, Shepherd SP, Giranda VL, Aghajanian C. A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic oncology group study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5507. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5507

31. Bellmunt J, Sonpavde G, De Wit R, Choueiri TK, Siefker-Radtke AO, Plimack ER, Lewis NM, Brown H, Mai Y, Gause CK, Kaufman DR, Bajorin DF. KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4571.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4571

32. Berdeja JG, Oki Y, Patel MR, Copeland A, Flinn I, Neelapu SS, Viner J, Wang J, Gerecitano JF, Younes A. Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8537. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8537

33. Berkman AM, Jones L, Crocker A, Brewster AM, Lakoski SG. Racial differences in 20-year cardiovascular outcomes among childhood and young adult cancer survivors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6548.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6548

34. Blinder VS, Eberle CE, Patil S, Ramirez J, McNish T, Min S, Bhagwati N, Lee S, Hudis CA, Oeffinger KC, Gany F. Ethnic disparities in the impact of breast cancer on the workforce: A pilot study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17600.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17600
35. Bowers DC, Moskowitz CS, Chou JF, Mazewski CM, Neglia JP, Armstrong GT, Leisenring WM, Robison LL, Oeffinger KC. Morbidity and mortality associated with subsequent meningiomas among childhood cancer survivors exposed to cranial radiotherapy: A report from the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10000.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10000
36. Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D'Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (pts) with advanced sarcomas. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS10578.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS10578
37. Buzaglo JS, Karten C, Miller MF, Greer JA, Weiss ES, Mauro MJ. Treatment-adherence beliefs and behaviors in patients with chronic myeloid leukemia (CML). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9558. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9558
38. Castillo JJ, Glezerman IG, Boklage SH, Chiodo JA, Tidwell BA, Lamerato LE, Schulman KL. Prognostic significance of hypervolemic or euvoletic hyponatremia in patients with lymphoma, breast, lung, or colorectal cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17554.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17554
39. Cercek A, Park V, Yaeger RD, Reidy DL, Kemeny NE, Stadler ZK, Segal NH, Varghese AM, Saltz L. Oxaliplatin can be safely infused at a rate of 1mg/m²/min. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e14665. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e14665
40. Cercek A, Zauderer MG, Rimner A, Rusch VW, Adusumili PS, Nash GM, Hmeljak J, Ladanyi M, Krug LM. Confirmation of high prevalence of BAP1 inactivation in mesothelioma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7564.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7564
41. Chaff JE, Naidoo J, Dunphy M, Woo K, Sima CS, Downey RJ, Travis WD, Kris MG. Utility of 18F-FDG PET and CT to assess response to neoadjuvant chemotherapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7548. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7548
42. Cheung WY, Renfro LA, Yothers G, Gray RG, Haller DG, Twelves C, Andre T, Van Cutsem E, Saltz L, Grothey A, Labianca R, Alberts SR, Schmoll H, Guthrie K, De Gramont A, Allegra CJ, Sargent DJ, ACCENT Collaborative Group. Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6580. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6580
43. Chi P, Qin L, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Shoushtari AN, Condly MM, Konen T, Fruauff A, DeMatteo RP, Singer S, Hwang S, Antonescu CR, Tap WD. A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10507.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10507
44. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemester FB, Fayad L, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and

NK-cell lymphoma (T/NKCL). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8538.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8538

45. Choueiri TK, Hahn NM, Alva AS, Lauer RC, Dreicer R, Picus J, Pili R, Balar AV, Sonpavde G, Hoffman-Censits JH, Guancial EA, Alter R, Regan MM, Jacobs C, Stewart PS, Pal SK, Rosenberg JE. The borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4577.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4577

46. Clemens MW, Butler CE, Hunt K, Fanale MA, Horwitz SM, Liu H, McCarthy C, Nastoupil LJ, Liu J, Medeiros LJ, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: Proposal for optimal management. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8550.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8550

47. Collisson EA, Zill O, Greene C, Leng J, Siew L, Vu MA, Kelley RK, Ko AH, Atreya CE, Van Loon K, Bivona TG, Tempero MA, Sebisano D, Munster PN, Talasz A. Prospective evaluation of circulating tumor DNA sequencing in pancreaticobiliary carcinomas. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 107. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/107

48. Comen EA, Kleppe M, Wen YH, Rapaport F, Granot Z, Socci ND, Viale A, You D, Benezra R, Weigelt B, Brogi E, Berger MF, Reis-Filho J, Levine RL, Norton L, Bastian L, Keller M. Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11000.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11000

49. Connell LC, Harding JJ, Lowery MA, Kemeny NE, Cercek A, Abdelgawad MI, O'Reilly EM, Saltz L, Abou-Alfa GK. Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15146.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15146

50. Copur MS, Brussow K, Wagoner J, Ramaekers RC, Gonen M, Percich S, Gauchan D, Nawal L, Mickey M, Norvell M, Clark D, Islam KM. Cancer genetic counseling services (GCS) at saint francis cancer treatment center (SFCTC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e12506.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12506

51. Coutre S, Barrientos JC, Brown JR, De Vos S, Furman RR, Keating MJ, O'Brien SM, Pagel JM, Sharman JP, Zelenetz AD, Newcomb T, Cho Y, Aguilar C, Dreiling L. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e18030. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e18030

52. Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe MA, Baker N, Oliner KS, Zhang Y, Hoang T, Sidhu R, Catenacci DVT. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4000.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4000

53. Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, Greenberg D, Moller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT. Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16040.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16040

54. D'Angelo SP, Shoushtari AN, Landa J, Kuk D, Sanchez AJ, Lala B, Dickson MA, Gounder MM, Keohan ML, Tap WD. Metastatic non-uterine leiomyosarcoma: Prognostic factors, overall survival and chemotherapy outcomes. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10574. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10574

55. Danila DC, Fleisher M, Carrasquillo JA, Gilbert H, Morris MJ, Bellomo LP, Hendrikx PJ, Szafer-Glusman E, Herkal A, Patel C, Schreiber NA, Curtis KR, Maslyar DJ, Lemahieu V, Fine BM, Mamounas MJ, Ungewickell AJ, Lackner MR, Scher HI, Kabbarah O. STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5029. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5029

56. Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9005. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9005

57. Dave V, Roberts R, Griffo Y, Moryl N, Tickoo R, Cubert K, Gulati A, Hung J, Puttanniah V, Horn S, Brown P, Malhotra V, Glare PA, Inturrisi C. Association of severe pain with poor response to opioids, psychological distress, and aberrant drug taking behaviors in a large cohort of cancer patients. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9600. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9600

58. Davis JW, Crawford ED, Shore N, Scardino PT, Tward JD, Harrison L, Evans B, FitzGerald L, Stone S, Brawer MK. Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5033. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5033

59. De Azambuja E, Saura C, Oliveira M, Dubsky PC, Zardavas D, Fesl C, Bardia A, Lin R, Fredrickson JO, Parmar H, Singel SM, Hsu JY, Piccart-Gebhart MJ, Gnant M, Baselga J. LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS627. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS627

60. de Velasco G, Fay AP, Culhane A, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Rathmell K, Albiges LK, Hsieh J, Heng DYC, Signoretti S, Choueiri TK. Prognostic value of genomic signatures in metastatic clear cell renal cell carcinoma (mRCC) using the cancer genome atlas (TCGA) data. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4560. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4560

61. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze S, Staddon AP, Milhem MM, Elias AD, Ganjoo KN, Tawbi HA, Van Tine BA, Spira AI, Dean AP, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel S. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10503. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10503

62. Diamond L, Gany F, Pottinger TD, Samedy P, Dong A, Martin S, Korenstein D. Influence of language barriers on hospital readmissions in cancer patients. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17583. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17583

63. Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN, Motzer R. Crossover in oncology clinical trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15592. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15592
64. Dickler MN, Barry WT, Cirincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake D, Hahn OM, Schneider BP, Tripathy D, Winer EP, Hudis CA. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (alliance). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 501. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/501
65. Douglas M, Allen K, Sweeney J, O'Brien SM, Flinn I, Horwitz SM, Byrd JC, Patel MR, Kahl BS, Foss FM, Porcu P, Kelly V, Stern H. Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K- δ , γ inhibitor. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7072. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7072
66. Drilon AE, Eaton A, Schindler K, Gounder MM, Smith GL, Vulih D, Harris PJ, Spriggs DR, Ivy P, Iasonos A, Lacouture ME, Hyman DM. Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the national institutes of health cancer therapy evaluation program (CTEP). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2546. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2546
67. Drilon AE, Sima CS, Somwar R, Smith R, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG, Rizvi NA. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8007. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8007
68. Dunn L, Ho AL, Haque S, Fury MG, Baxi SS, Cullen G, Pfister DG, Sherman EJ. Assessment of second-line VEGF-inhibitor therapy in radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17064. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17064
69. Dunphy M, Harding JJ, Lewis JS, Mellinghoff IK, Omuro AMP, Hsieh J, Zhang H, Zanzonico P, Venneti S, Carlin S, Younes A, Gerecitano JF, Lyashchenko SK, Harris L, Lashley A, Kung H, Thompson CB, Kelsen DP. Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11014. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11014
70. Eaton A, Iasonos A, Gounder MM, Pamer E, Drilon AE, Vulih D, Smith GL, Ivy P, Spriggs DR, Hyman DM. Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17674. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17674
71. Effinger KE, Fisher PG, Ness KK, Krull KR, Marina N, Stovall M, Oeffinger KC, Armstrong GT, Robison LL, Nathan PC, Leisenring WM, Hudson MM. Longitudinal evaluation of health status and chronic conditions in aging pediatric astrocytoma survivors: A childhood cancer survivor study (CCSS) report. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10067. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10067
72. Eguchi T, Kyuichi K, Evans B, Sima CS, Davis T, Hamilton SA, Yager K, Kolquist KA, Jones JT, Hartman A, Adusumilli PS. Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7522. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7522
73. Elkin EB, O'Neill C, Atoria CL, O'Reilly EM, Bach P. The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6545. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6545

74. Elster N, Eustace AJ, Fan Y, Naidoo J, Fay J, Kay E, Carr A, Breathnach OS, Morris PG, Grogan W, Hill AD, Power C, Allen MJ, Kennedy S, Crown J, Gallagher WM, Toomey S, Hennessy B. Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 615. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/615
75. Eng J, Li BT, Hsu M, Chaft JE, Arcila ME, Kris MG. Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8068. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8068
76. Epstein AS, Prigerson HG, Saltz L, O'Reilly EM, Shah MA, Maciejewski PK. "Months, not years": Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9549. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9549
77. Eroglu Z, Kim DW, Johnson DB, Algazi AP, Munhoz RR, Liniker E, Kong B, Khurana N, Chmielowski B, Sosman JA, Scolyer RA, Carlino MS, Postow MA, Hwu W, Long GV, Ribas A. Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9011. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9011
78. Faltas B, Gennarelli RL, Nguyen DP, Tagawa ST, Elkin EB. Use and outcomes of metastasectomy in older patients with urothelial cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15506. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15506
79. Federico M, Bellei M, Luminari S, Horwitz SM, Montoto S, Zucca E, Pileri SA, Ko Y, Zinzani PL, Connors JM, Foss FM, Polliack A, Cabrera ME, Kim WS, Spina M, De Souza CA, Bobillo Varela S, Dlouhy I, Advani RH, Vose J, T-Cell Project . CD30+ expression in peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-cell project. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8552. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8552
80. Feldman DR, Bagrodia A, Lee B, Lee W, Al-Ahmadie H, Cha EK, Sfakianos J, Iyer G, Zabor EC, Ostrovnaya I, Eng J, Arcila ME, Chaganti RSK, Schultz N, Reuter VE, Bains MS, Sheinfeld J, Carver BS, Bosl GJ, Solit DB. Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4510. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4510
81. Feldman JL, Morris MJ, Martinez DF, Tagawa ST, Nanus DM, Solomon SB, Carrasquillo JA, Reuter VE, Lewis JS, O'Donoghue JA, Slovin SF, Rathkopf DE, Gonen M, Beylertgil V, Durack JC, Cheal SM, Bander NH, Scher HI, Larson SM, Pandit-Taskar N. Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using zirconium-89 labeled antiprostata-specific membrane antigen (PSMA) antibody J591. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5054. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5054
82. Fleisher M, Danila DC, Fizazi K, Hirmand M, Selby B, Phung D, De Bono JS, Scher HI. Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5035. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5035
83. Flinn I, Hamlin PA, Strickland DK, Pandey A, Birrell M, Coffey G, Leeds J, Curnutte JT, Burger JA, Wagner-Johnston ND, Patel MR. Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8531. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8531
84. Flynn KE, Jeffery DD, Andersen BL, Siston AK, Jhingran A, Baron SR, Reese JB, Coady DJ, Carter J, Barbera LC. Self-reported sexual function measures administered to female cancer patients: A

systematic review, 2008-2014. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e20592. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20592

85. Fu J, Gucaip A, Zauderer MG, Epstein AS, Kris MG, Keesing J, Caroline A, Megerian M, Eggebraaten T, DeLima R, Setnes M, Wildt P, Seidman AD. Steps in developing watson for oncology, a decision support system to assist physicians choosing first-line metastatic breast cancer (MBC) therapies: Improved performance with machine learning. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 566. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/566

86. Fuchs CS, Tabernero J, Al-Batran S, Chau I, Ilson DH, Van Cutsem E, Ferry D, Emig M, Melemed AS, Vanvoorden V, Hsu Y, Xu Y, Sashegyi A, Das M, Shah MA. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4131. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4131

87. Funakoshi T, Suzuki M, Muss HB. A comparison of toxicity profiles between standard and lower dose capecitabine (CAP) in breast cancer (BC): A meta-analysis. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1028. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1028

88. Gainer JL, Sheehan J, Larner JM, Jones DR. Use of a novel radio-sensitizer for treatment of GBM. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2031. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2031

89. Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, West HJ, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter AH, Bordogna W, Balas B, Puig O, Henschel V, Ou SI, NP28761 Study Investigators . A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8019. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8019

90. Gelhorn H, Tong S, MacLaine G, Healey JH, Bukata SV, Keedy VL, Anthony SP, Wagner AJ, Von Hoff DD, Singh AS, Becerra C, Hanlon J, Lenderking W, Murray L, Hsu HH, Lin PS, Tap WD. Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10521. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10521

91. Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, Gomes DaGama E, Uddin M, Chiosis G, Lewis JS, Lyashchenko SK, Larson SM, Pressl C, Dunphy M. Phase I trial of the HSP-90 inhibitor PU-H71. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2537. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2537

92. Gertz MA, Landau HJ, Comenzo R, Seldin DC, Weiss BM, Zonder JA, Walling J, Kinney G, Koller M, Liedtke M. Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8514. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8514

93. Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Goldman JW, Juergens RA, Borghaei H, Ready N, Gerber DE, Nathan FE, Shen Y, Harbison C, Rizvi NA. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8025. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8025

94. Gibson TM, Liu W, Armstrong GT, Srivastava DK, Hudson MM, Leisenring WM, Mertens A, Klesges R, Oeffinger KC, Nathan PC, Robison LL. Longitudinal smoking patterns in survivors of childhood cancer: A childhood cancer survivor study (CCSS) update. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10075. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10075
95. Goldfarb SB, Bedoschi G, Grunblatt E, Goswami S, Cigler T, Quistorff J, Pacheco F, Stobezki R, Robson ME, Moy F, Hudis CA, Patil S, Dickler MN, Oktay K. The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve and menses. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9522. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9522
96. Goldfarb SB, Stevens J, Brouwer S, Benaïm E, Narain NR, Sarangarajan R, Kracunas A, Jimenez JJ, Belum VR, Ciccolini K, Kehn D, Lacouture ME. First in-human, phase I study of the safety, tolerability and pharmacokinetics (PK) of BPM31543 (topical calcitriol solution) in adult cancer patients: Preliminary results. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e20682. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20682
97. Goldman D, Sarkaria IS, Rizk NP, Grosser R, Ghanie A, Rusch VW, Bains MS, Burkhalter JE, Jones DR, Sima CS. Patient-reported symptom frequency and distress after open and minimally invasive esophagectomy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17724. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17724
98. Golshan M, Cirrincione CT, Carey LA, Sikov WM, Berry DA, Burstein HJ, Overmoyer B, Henry NL, Somlo G, Port ER, Winer EP, Hudis CA, Ollila DW. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (alliance). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1007. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1007
99. Gomez-Roca CA, Cassier PA, Italiano A, Cannarile M, Ries C, Brillouet A, Mueller C, Jegg A, Meneses-Lorente G, Baehner M, Abiraj K, Loirat D, Toulmonde M, D'Angelo SP, Weber K, Campone M, Ruettinger D, Blay J, Delord J, Le Tourneau C. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3005. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3005
100. Gopal AK, Bartlett NL, Levy R, Houot R, Smith SD, Segal NH, Thall AD, Mugundu G, Huang B, Davis C, Kohrt HE. A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3004. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3004
101. Gounder MM, Zer A, Tap WD, Gupta AA, Keohan ML, Dickson MA, D'Angelo SP, Chi P, Tanner LR, Konen T, Rashal T, McCauley D, Saint-Martin J, Carlson R, Marshall T, Shacham S, Mirza MR, Kauffman M, Schwartz G, Razak ARA. A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10569. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10569
102. Grigorenko A, May P, Kastango N, Thaler HT, Wagner I, Caroline A, Kris MG, Zauderer MG. Electronic medical record as a research tool: Virtual clinical trial comparing pemetrexed and gemcitabine, both given with cisplatin, in patients with lung adenocarcinomas. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8024. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8024
103. Grisham RN, Gordon MS, Harb WA, Aghajanian C, McMeekin DS, McKinley K, Anderson LR, Chavira R, Christy-Bittel J, Barrett E, Moore KN. A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5516. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5516

104. Gutierrez M, Giaccone G, Harper HD, Liu SV, Fang B, Ruiz J, Hinson JM, Orlemans EO, Drilon AE. A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e19033. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e19033
105. Hahn NM, Picus J, Bambury RM, Pal SK, Hart LL, Grivas P, Milowsky MI, Alva AS, Sonpavde G, Mortazavi A, Bellmunt J, Guancial EA, Gupta S, Chao RC, Collier MA, Christensen J, Chen I, Rosenberg JE. A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4575. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4575
106. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Ernstoff M, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger CK, Heng DY, Spratlin JL, Shen Y, Gagnier P, Amin A. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4516. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4516
107. Hammers HJ, Plimack ER, Sternberg C, McDermott DF, Larkin JMG, Ravaud A, Rini BI, Sharma P, Bhagavatheeswaran P, Gagnier P, Motzer R. CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4578. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4578
108. Harding JJ, Abu Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, O'Reilly EM, Capanu M, Saltz L, Abou-Alfa GK. Hepatocellular carcinoma (HCC) and bone metastases (mets). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15129. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15129
109. Harding JJ, Telli ML, Munster PN, Le MH, Molineaux C, Bennett MK, Mittra E, Burris HA, Clark AS, Dunphy M, Meric-Bernstam F, Patel MR, DeMichele A, Infante JR. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2512. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2512
110. Harshman LC, Werner L, Wong Y, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Recine F, Bellmunt J, Galsky MD, RISC Investigators. Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4524. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4524
111. Hechtman JF, Arcila ME, Cheng DT, Solit DB, Yaeger RD, Hyman DM, Berger MF, Shia J, Vakiani E, Zehir A, Ladanyi M. Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11071. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11071
112. Ho AL, Foster NR, Meyers JP, Deraje Vasudeva S, Katabi N, Antonescu CR, Pfister DG, Horvath LE, Erlichman C, Schwartz GK. Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6039. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6039
113. Hobday TJ, Yin J, Pettinger A, Strosberg JR, Reidy DL, Chen HX, Erlichman C. Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor

(PNET). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4096.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4096

114. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen MF, Ernstoff MS, Minor DR, Salama A, Taylor MH, Ott PA, Horak CE, Gagnier P, Wolchok JD. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9004. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9004

115. Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralto S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Martin TG, Shea TC, Anderson KC, McCarthy PL. Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8523. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8523

116. Hou Z, Belum VR, Palomba ML, Loic Y, Sibaud V, Lacouture ME. Systematic review of rash in cancer patients receiving ibrutinib and idelalisib. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e12655. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12655

117. Hsieh J, Chen D, Wang P, Chen Y, Redzematovic A, Marker M, Patel P, Chevinsky M, Bhanot U, Pinciroli P, Bouvier N, Huberman KH, Berger MF, Socci ND, Cheng E, Lee W, Knox JJ, Voss MH, Voi M, Motzer R. Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4509. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4509

118. Hyman DM, Sill M, Cho JK, Lankes HA, Piekarz R, Hensley ML. A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic oncology group study (GOG-0231D). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16512. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16512

119. Infante JR, Janku F, Tolcher AW, Patel MR, Sullivan RJ, Flaherty K, Carvajal RD, Varghese AM, Wong DJL, Sznol M, Sosman JA, Wang-Gillam A, Burris HA, Ribas A, Patel SP, Welsch DJ, Saha S. Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2506. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2506

120. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJL, Falchook GS, Patel MR, Pant S, Whiteside M, Bendell JC, Bauer TM, Janku F, Javle MM, Hong DS, Oft M. A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3017. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3017

121. Iyengar NM, Morris PG, Zhou XK, Wang H, Gucalp A, Giri DD, Harbus MD, Park J, Park SS, Morrow M, Hudis CA, Dannenberg A. White adipose tissue inflammation and breast cancer progression. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11001. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11001

122. Jacobsen PB, Rowland JH, Paskett ED, Van Leeuwen F, Moskowitz CS, Katta S, Wollins D, Robison LL. Results of the ASCO survey of cancer survivorship research: Summary and implications. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9567. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9567

123. Jagsi R, Hawley ST, Griffith KA, Janz NK, Kurian AW, Ward KC, Hamilton AS, Katz SJ, Morrow M. Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients: Knowledge and physician influence. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1011. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1011
124. Jagsi R, Kurian AW, Griffith KA, Hamilton AS, Ward KC, Hawley ST, Morrow M, Katz SJ. Genetic testing decisions of breast cancer patients: Results from the iCanCare study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1541. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1541
125. Janelins MC, Yao S, Mustian KM, Peppone LJ, Heckler CE, Esparaz B, Giguere JK, Irwin R, Neilan B, Ahles T, Ambrosone CB, Morrow GR. Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter signaling, longevity, and inflammation pathways in 366 breast cancer (BC) patients and 366 age-matched cancer-free controls: A prospective, nationwide, longitudinal URCC NCORP study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9503. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9503
126. Janjigian YY, Ku GY, Chou JF, Capanu M, Siebel M, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Kelsen DP, Imtiaz T, Ilson DH. Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4053. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4053
127. Jurcic JG, Ravandi F, Pagel JM, Park JH, Smith BD, Douer D, Levy MY, Estey E, Kantarjian HM, Earle D, Cicic D, Scheinberg DA. Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7050. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7050
128. Kaczmar JM, Everett J, Ruth K, Stoffel EM, Stoll J, Kupfer S, Hampel H, Stadler ZK, Gaddam P, Rybak C, Slavin TP, Terdiman JP, Blanco A, Hall MJ. Sarcoma: A lynch syndrome (LS)-associated malignancy? *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1516. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1516
129. Kaufman H, Hamid O, D'Angelo SP, Yuan G, Chin KM, Bhatia S, Cuillerot J, Nghiem P. A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic merkel cell carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS9086. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9086
130. Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Kingham TP, Allen PJ, Fong Y, Cercek A, D'Angelica MI. Improvement in long-term survival in patients with metastatic colorectal cancer (CRC) after liver resection with modern chemotherapy and hepatic arterial infusion (HAI). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3563. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3563
131. Khasraw M, Mukaro VR, West L, Brandt C, Woollett AM, Edwards M, Spokes R, Mitchell G, Prince K, Hayes TM, Collins IM, Guminski AD, Baron-Hay SE, Olesen IH, Bryan J, Bowles S, Wong SF, Ashley DM, Patil S. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e12025. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12025
132. Khoury HJ, Baccarani M, Guilhot F, Hochhaus A, Hughes TP, Lipton JH, Lustgarten S, Yanase K, Conlan MG, Cortes JE, Deininger MWN, Kantarjian HM, Shah NP, Talpaz M, Mauro MJ. Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7049. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7049

133. Kieran MW, Hargrave DR, Cohen KJ, Aerts I, Dunkel IJ, Hummel TR, Jimenez I, Pearson AD, Pratilas CA, Whitlock J, Bouffet E, Shen WV, Broniscer A, Bertozzi A, Sandberg JL, Florance AM, Suttle BB, Haney P, Russo MW, Geoerger B. Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), langerhans cell histiocytosis (LCH), and other solid tumors (OST). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10004. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10004
134. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung Fy, Yadav S, Patel PM, Geoffrois L, Schiff E, Niolat J, Berkowitz N, Voi M, Motzer R. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4554. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4554
135. Kreitman RJ, Arons E, Still K, Tallman MS, Stetler-Stevenson M, Yuan C, FitzGerald DJ, Pastan I. Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7079. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7079
136. Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains MS, Rizk NP, Chou JF, Capanu M, Wu AJ, Goodman KA, Ilson DH, Ku GY. Changing chemotherapy (C) with concurrent radiation (RT) followed by surgery after sub-optimal FDG-PET response to induction chemotherapy improves outcomes in locally advanced (LA) esophageal adenocarcinoma (EA). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4054. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4054
137. Kris MG, Gucalp A, Epstein AS, Seidman AD, Fu J, Keesing J, Caroline A, Megerian M, Eggebraaten T, DeLima R, Setnes M, Zauderer MG. Assessing the performance of watson for oncology, a decision support system, using actual contemporary clinical cases. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8023. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8023
138. Kris MG, Johnson BE, Kwiatkowski DJ, Wistuba II, Berry LD, Haura EB, Socinski MA, Ramalingam SS, Glisson BS, Waqar SN, Otterson GA, Schiller JH, Garon EB, Cetnar JP, Politi KA, Brahmer JR, Sequist LV, Lovly CM, Kugler K, Bunn PA. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung cancer mutation consortium (LCMC 2.0). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8094. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8094
139. Krug LM, Zauderer MG, Adusumili PS, McGee E, Sepkowitz K, Klang M, Yu YA, Scigalla P, Rusch VW. Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7559. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7559
140. Kunz PL, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Schrijver I, Reidy DL, Strosberg JR, O'Dwyer PJ, Benson AB. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN cancer research group (E2211). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4145. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4145
141. Lacouture ME, Belum VR, Kehn D, Cercek A, Kemeny NE. A phase III randomized double-blind study of prophylactic topical dapsone 5% versus moisturizer for cetuximab-induced papulopustular (acneiform) rash. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS9638. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9638
142. Lacouture ME, Keefe DMK, Sonis ST, Giri N, Wang T, Reisman A, Sbar E, Gernhardt DR, Jatoi A. Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or

diarrhea improvement from corticosteroids or probiotics. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e19049. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e19049

143. Lacouture ME, Tang JY, Rogers GS, Olencki T, Kudchadkar RR, Yoo SS, Guillen J, Mun Y, Dawson KL, Sekulic A. The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9023. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9023

144. Lancet JE, Othus M, DeAngelo DJ, Coutre S, Komrokji RS, Tallman MS, Litzow MR, Appelbaum FR. Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7016. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7016

145. Land SR, Warren GW, Moinpour C, Ostroff JS, Crafts J, Folz J, Gulley JL, Szabo E, Chollette V, Brandon TH, Duffy S, Hatsukami DK, Dresler CM, Gritz ER, Schnoll R, Sarna L, Rigotti N, Buckner JC, Mitchell SA, Toll B. Standardizing measurement of tobacco use in cancer clinical trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9550. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9550

146. Landers M, Greene S, Schreiber NA, Rodriguez A, Bambury RM, Danila DC, Rathkopf DE, Fleisher M, Louw J, Jendrisak A, Marrinucci D, Dittamore RV, Scher HI. Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11035. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11035

147. Landsburg DJ, Petrich AM, Abramson JS, Sohani A, Press OW, Cassaday RD, Chavez JC, Song KW, Zelenetz AD, Gandhi M, Shah NM, Fenske T, Jasso J, Medeiros LJ, Yang DT, Nabhan C. Analysis of "double-hit" lymphoma cases by genetic subtype. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8543. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8543

148. Lee AY, Agaram NP, Qin L, Brennan MF, Singer S. Primary high-grade myxofibrosarcoma/pleomorphic malignant fibrous histiocytoma: Percent myxoid component to improve outcome prediction. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10556. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10556

149. Lee C, Motzer R, Hoetker A, Akin O, Molina AM, Gold TM, Patil S, Gowrishankar B, Houldsworth J. Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4552. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4552

150. Leidner RS, Patel SP, Fury MG, Ferris RL, McDevitt JT, Lanasa MC, Glisson BS. A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS6083. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS6083

151. Li BT, Ross DS, Chaft JE, Hsu M, Kako S, Aisner DL, Kris MG, Varella-Garcia M, Arcila ME. Defining the spectrum and "overlap" of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8067. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8067

152. Liang L, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Alektiar KM, Abu-Rustum N, Makker V. Outcomes of stage IA polyp-limited vs endometrium-limited epithelial high grade endometrial

carcinoma (EMC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16500.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16500

153. Liedtke M, Merlini G, Landau HJ, Comenzo R, Seldin DC, Weiss BM, Zonder JA, Walling J, Kinney G, Koller M, Gertz MA. The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8614.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8614

154. Lin CC, Bruinooge SS, Kirkwood KM, Olsen CC, Bajorin DF, Jemal A, Giordano SH, Goldstein M, Guadagnolo BA, Kosty MP, Hopkins S, Yu JB, Arnone A, Hanley AE, Stevens S, Hershman DL. Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17561. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17561

155. Lin X, Fleisher M, Omuro AMP, Shagabayeva L, Pentsova E. Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2072.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2072

156. Lin X, Fleisher M, Shagabayeva L, Omuro AMP, Pentsova E. Detection of cerebral spinal fluid (CSF) circulating melanoma cells (CMC) for the diagnosis of melanoma leptomeningeal metastasis (LM). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e13061.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e13061

157. Lipitz Snyderman AN, Sima CS, Elkin EB, Atoria CL, Anderson C, Blinder VS, Bach P. Physician-driven variation in non-recommended imaging for women with early stage breast cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6507.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6507

158. Litvak AM, Drilon AE, Rekhtman N, Pietanza MC, Chaft JE, Woo K, Paik PK, Kris MG, Riely GJ. Phase II trial of bortezomib in KRAS G12D mutant lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e19002. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e19002

159. Lo-Coco F, Tallman MS, Barnes G, Guerra I, Damera V, Martin M, Mueller UW. A meta-analysis of randomized clinical trials in acute promyelocytic leukemia (APL). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7040. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7040

160. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes EM, Bria E, Denkert C, Eidtmann H, Sotiriou C, Loi S, Andre F, Untch M, Conte PF, Piccart-Gebhart MJ, Von Minckwitz G, Baselga J. Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 511.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/511

161. Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Pitfield T, Molina A, Kheoh T, McCormack RT, Scher HI, De Bono JS. Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5014.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5014

162. Lowery MA, O'Reilly EM, Harding JJ, Salehi E, Hollywood E, Bradley M, Sophos NA, Ly M, Capanu M, Gerst SR, Saltz L, Abou-Alfa GK. A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15125.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15125

163. Lung BY, Valentino E, Gerst SR, Untch BR, Katz S, Strong VE, Raj NP, Olino K, Saltz L, Reidy DL. Low objective response and high toxicity to single-agent mitotane in patients with metastatic adrenocortical carcinoma (ACC): A 25 year experience at MSKCC. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4105. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4105
164. Madenci AL, Fisher S, Diller L, Goldsby RE, Leisenring WM, Oeffinger KC, Robison LL, Sklar CA, Stovall M, Weathers R, Armstrong GT, Yasui Y, Weldon CB. Intestinal obstruction in survivors of childhood cancer: A report from the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10071. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10071
165. Mallmann MR, Domroese CM, Fuhrmann C, Thangarajah F, Leitzen L, Ulhaas A, Bach F, Engelhardt D, Beier ED, Keyver-Paik M, Coch C, Kaiser C, Abramian A, Nuding B, Malter W, Kraemer S, Wirtz M, Rudlowski C, Zivanovic O, Kuhn WC. TabPRO trial: Tablet-based real-time detection of patient-reported outcomes during adjuvant outpatient chemotherapy for breast cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS9640. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9640
166. Manohar P, Sapir E, Eisbruch A, Spector ME, Prince ME, Shuman AG, Bradford CR, Chepeha DB, Wolf GT, Moyer J, Malloy KM, McLean SA, McKean EL, Bellile EL, Hanauer DA, Worden FP. Retrospective review of capecitabine as adjuvant therapy in high risk or recurrent squamous cell carcinoma of head and neck (SCCHN). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17043. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17043
167. Margolis J, Princic N, Doan J, Lenhart G, Motzer R. Analysis of real world treatment compliance in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4546. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4546
168. McFarland DC, Holland J, Holcombe RF. Effect of an inpatient hematology-oncology ward rotation on medical house staff interest in pursuing hematology-oncology as a career. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17559. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17559
169. McKay RR, Werner L, Harshman LC, Bellmunt J, Sweeney C, Rosenberg JE, VanAllen E, Walsh MK, Vaishampayan UN, McDermott DF, Choueiri TK. A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4559. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4559
170. McKee MJ, Trembath DG, Deal AM, Keith K, Midkiff BR, Nikolaishvilli-Feinberg N, Garrett A, Blackwell KL, Leone JP, Hamilton RL, Brufsky A, Morikawa A, Brogi E, Seidman AD, Ewend MG, Moschos SJ, Anders CK. Histopathological markers at craniotomy and outcome in breast cancer brain metastases. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2027. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2027
171. McNeish IA, Oza AM, Coleman RL, Scott CL, Konecny GE, Tinker A, O'Malley DM, Brenton J, Kristeleit RS, Bell-McGuinn K, Oaknin A, Leary A, Lin K, Raponi M, Giordano H, Goble S, Rolfe L, Yelensky R, Allen AR, Swisher EM. Results of ARIEL2: A phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5508. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5508
172. Mehta-Shah N, Lunning MA, Boruchov AM, Ruan J, Nair S, Lynch P, Byrne R, Moskowitz AJ, Matasar MJ, Gerecitano JF, Hamlin PA, Leonard J, Moskowitz CH, Myskowski PL, Querfeld C, Nolan P, Palomba ML, Straus DJ, Zelenetz AD, Horwitz SM. A phase I/II trial of the combination of romidepsin

and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8521.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8521

173. Merchant MS, Cristea MC, Stadtmauer EA, Tap WD, D'Angelo SP, Grupp SA, Holdich T, Binder-Scholl G, Jakobsen BK, Odunsi K, Rapoport A, Mackall C. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS3102. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS3102

174. Momtaz P, Park V, Panageas K, Guillen JD, Postow MA, Callahan MK, Wolchok JD, Chapman PB. Safety of infusing ipilimumab (ipi) over 30 minutes (min). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9046. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9046

175. Monk BJ, Grisham RN, Marth C, Banerjee SN, Hilpert F, Coleman RL, Pujade-Lauraine E, Pignata S, Mirza MR, Oza AM, del Campo JM, Oehler MK, James A, Christy-Bittel J, Barrett E, Boyd AP, Vergote I. The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS5610. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS5610

176. Moore KN, Varghese AM, Hyman DM, Callies S, Lin J, Wacheck V, Pant S, Bauer TM, Bendell JC. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 11075. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11075

177. Morikawa A, Jordan L, Rozner R, Patil S, Boire AA, Pentsova E, Seidman AD. Characteristics and outcomes of breast cancer patients with leptomeningeal metastasis at memorial sloan kettering cancer center (MSKCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2026. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2026

178. Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, Ryan CJ, Lorient Y, Fizazi K, Pandit-Taskar N, Garcia-Vargas JE, Lyseng K, Bloma M, Carrasquillo JA. Effects of radium-223 dichloride (ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5012. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5012

179. Morris MJ, Hilden P, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Dayan ES, Filipenko J, Acosta I, Heller G, Scher HI. Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5011. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5011

180. Motzer R, Alyasova A, Ye D, Karpenko A, Li H, Alekseev BY, Xie L, Kurteva GP, Kowalyszyn RD, Neron Y, Cosgriff T, Collins L, Brechenmacher T, Segal S, Morgan LM, Yang L. RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4518. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4518

181. Motzer R, Hutson T, Glen H, Michaelson D, Molina AM, Eisen T, Jassem J, Zolnieriek J, Maroto P, Mellado B, Melichar B, Tomasek J, Kim H, Wood K, Dutcus C, Larkin JMG. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4506. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4506

182. Mueller EL, Hutchinson RJ, Goodman P, Leisenring WM, Sklar CA, Hudson MM, Ness KK, Armstrong GT, Robison LL, Stovall M, Oeffinger KC, Nathan PC. Long-term risks for chronic medical conditions and premature mortality in survivors of pediatric soft tissue sarcoma: A report from the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10013. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10013
183. Mueller JJ, Alvi FA, El Haraki AS, Eriksson AG, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi D, Abu-Rustum N, Zivanovic O. Neoadjuvant chemotherapy (NACT) selection for advanced stage ovarian cancer (AOC) at a comprehensive cancer center. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16579. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16579
184. Munhoz RR, Merghoub T, Emerson RO, Callahan MK, Wolchok JD, Postow MA. Investigation of inpatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9075. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9075
185. Munhoz RR, Pereira AAL, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1050. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1050
186. Muss HB, Berry DA, Cirincione CT, Theodoulou M, Hurria A, Cohen HJ, Partridge A, Norton L, Hudis CA, Winer EP. Standard chemotherapy versus capecitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1022. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1022
187. Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic oncology group study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5592. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5592
188. Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini BI, Hammers HJ. Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4566. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4566
189. Naidoo J, Steele K, Sima CS, Yuan J, Robbins PB, Moreira AL, Pietanza MC, Wolchok JD, Riely GJ, Rizvi NA. Defining the immunologic phenotype of thymic epithelial tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7516. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7516
190. Naidoo J, Woo K, Sima CS, Finley DJ, Travis WD, Rusch VW, Kris MG, Zauderer MG. Prognostic significance of a diagnosis of multiple lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7545. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7545
191. Ness KK, Hudson MM, Jones KE, Leisenring WM, Stovall M, Green DM, Neglia JP, Henderson TO, Casillas JN, Ford J, Effinger KE, Oeffinger KC, Armstrong GT, Robison LL, Nathan PC. Temporal trends in health status among adults in the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10020. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10020

192. Nuciforo P, Aura C, Thyparambil SP, Vilaro M, Garrido-Castro AC, Peg V, Jimenez J, Hoos WA, Burrows J, Hembrough TA, Perez-Garcia JM, Cortes J, Scaltriti M. HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 605.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/605
193. O'Cearbhaill RE, Hyman DM, Tew WP, Iasonos A, Cangemi NA, Aghajanian C, Bell-McGuinn KM, Makker V, Hensley ML, Konner JA, Grisham RN, Diaz-Macinnis K, Sabbatini P, Spriggs DR. Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5572.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5572
194. Oliveira M, Saura C, Gonzalez-Martin A, Andersen JC, Fisher JG, Calvo I, Ciruelos E, Gil M, De La Pena L, Llobet-Canela M, Choi Y, Jia S, Yalamanchili S, Singel SM, Patel PH, Baselga J, Isakoff SJ. FAIRLANE: A phase II randomized, double-blind, study of the akt inhibitor ipatasertib (ipat, GDC-0068) in combination with paclitaxel (pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS1112.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS1112
195. Omuro AMP, Zehir A, Cheng DT, Berger MF, Hyman DM, Solit DB, Baselga J, Ladanyi M, Arcila ME, Hameed M, Sabbatini P, DeAngelis LM, Gutin PH, Rosenblum M, Mellinghoff IK, Tabar V, Chan TA, Briggs S, Huse JT, Brennan CW. Is next generation sequencing (NGS) ready for routine clinical practice in gliomas? results of a prospective study utilizing the MSK-IMPACT assay. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2057.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2057
196. O'Reilly EM, Mahalingam D, Roach JM, Schultes BC, Rosano ME, Miller PJ, Wolf J, Flaherty K, Ryan DP. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4114.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4114
197. O'Reilly EM, Walker C, Clark J, Brill KJ, Dawkins FW, Bendell JC. JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4146.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4146
198. Ott PA, Callahan MK, Odunsi K, Park AJ, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD. A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS3099.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS3099
199. Owens CN, Iannotta A, Gerecitano JF, Matasar MJ, Noy A, Moskowitz CH, Drullinsky P, Palomba ML, Straus DJ, Horwitz SM, Zelenetz AD, Portlock CS, Kumar A, Hamlin PA. Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8571. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8571
200. Oxnard GR, Ramalingam SS, Ahn M, Kim S, Yu HA, Saka H, Horn L, Goto K, Ohe Y, Cantarini M, Frewer P, Lahn M, Yang JC. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2509.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2509

201. Page DB, Mariotti V, Davydov O, Patil S, Hans D, Hudis CA, Farooki A, Fornier MN. A combined screening approach of fracture (fx) risk algorithm (FRAX) and trabecular bone score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 574. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/574
202. Page DB, Wen YH, Brogi E, Yuan J, Emerson RO, Patil S, Dang CT, Norton L, Hudis CA, McArthur HL. Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 609. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/609
203. Paik PK, Drilon AE, Yu HA, Krug LM, Rekhtman N, Borsu L, Ginsberg MS, Berger MF, Ladanyi M, Rudin CM. Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8021. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8021
204. Parikh R, Grossbard ML, Harrison LB, Yahalom J. Overall survival in patients with hodgkin lymphoma: Disparities by insurance status. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8569. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8569
205. Park JH, Riviere I, Wang X, Bernal Y, Purdon T, Halton E, Curran KJ, Sauter CS, Sadelain M, Brentjens RJ. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7010. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7010
206. Patel MR, Bauer TM, Liu SV, Drilon AE, Wheler JJ, Shaw AT, Farago AF, Ou SI, Luo D, Yeh L, Hornby Z, Senderowicz AM, Lim J. STARTRK-1: Phase 1/2a study of entrectinib, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2596. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2596
207. Peterson LL, Hurria A, Feng T, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Glezerman IG, Katheria V, Zavala L, Smith DD, Tew WP. Association between renal function and chemotherapy-related toxicity in older adults with cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9509. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9509
208. Pietanza MC, Spira AI, Jotte RM, Gadgeel SM, Mita AC, Hart LL, Gluck WL, Chiang AC, Liu SV, Kapoun AM, Xu L, Hill D, Dupont J, Spigel DR, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7508. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7508
209. Pietanza MC, Won HH, Rekhtman N, Wang L, Travis WD, Krug LM, Varghese AM, Paik PK, Riely GJ, Zakowski MF, Ladanyi M, Berger MF, Kris MG, Rudin CM. Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7518. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7518
210. Pilewskie ML, Olcese C, Patil S, Van Zee KJ. Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 560. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/560
211. Pinciroli P, Iyer G, Won HH, Canevari S, Colecchia M, De Braud FG, Daidone MG, Giannatempo P, Raggi D, Pennati M, Zaffaroni N, Nicolai N, Salvioni R, Pierotti M, Solit DB, Rosenberg JE, Berger MF, Necchi A. Molecular signature of patients with pre-treated urothelial carcinoma (UC) achieving

extreme responses to pazopanib (PZP) salvage therapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15514. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15514

212. Pinker K, Riedl C, Ong L, Jochelson MS, Ulaner G, Dickler MN, Weber W. Is response classification with PERCIST in stage IV breast cancer influenced by the number of lesions assessed? *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e12004. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12004

213. Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman B, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Xu L, Waxman I, Motzer R. Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4553. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4553

214. Prockop S, Doubrovina E, Baroudy K, Boulad F, Khalaf R, Papadopoulos EB, Sauter CS, Szenes V, Suser S, Wasilewski G, Ruggiero J, O'Reilly RJ. Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+B-cell lymphomas post hematopoietic and organ allografts. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10016. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10016

215. Proverbs-Singh TA, Cadoo KA, Torre G, Patil S, Gucalp A, Dang CT, Hudis CA, Glezerman IG, Traina TA. Prevalence of hypomagnesemia in patients with HER2-positive breast cancer receiving pertuzumab treatment. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e11608. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e11608

216. Radosa JC, Eaton A, Stempel M, Khander A, Liedtke C, Solomayer E, Gunthner-Biller M, Morrow M, King TA. Evaluation of local and distant recurrences pattern in patients with triple negative breast cancer according to age. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1095. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1095

217. Raj NP, Valentino E, Tang LH, Capanu M, Basturk O, Klimstra D, Reidy DL. Treatment response and outcomes of grade 3 (G3) pancreatic neuroendocrine carcinomas (HGNEC) based on pathologic differentiation. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15185. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15185

218. Rathkopf DE, Attard G, Efstathiou E, Yu MK, Griffin TW, Todd MB, Wu D, Kheoh T, Zhao X, Saad F. A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS5071. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS5071

219. Raut CP, Espat NJ, Maki RG, Araujo DM, Keir CH, Williams TF, DeMatteo RP. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10537. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10537

220. Reardon DA, Dietrich J, Kaley TJ, Gan HK, Dunn GP, Cloughesy TF, Lim M, Clarke JL, Park AJ, Pan LS, Lai DW, Karakunnel JJ, Robbins PB, Narwal R, Venhaus RR. Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS2077. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS2077

221. Rego JFDM, Medeiros RSS, Braghiroli MIFM, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Galvao B, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy. *ASCO Meeting Abstracts*. 2015

May 18; 33(15_suppl): e15183.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183

222. Rego JFDM, Medeiros RSS, Braghiroli MIFM, Galvao B, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Castro G, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e15176.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176

223. Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, Linette GP, Ascierto PA, Kuzel T, Algazi AP, Postow MA, Nathan PD, Curti BD, Robbins PB, Li X, Blake-Haskins JA, Gordon MS. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3003.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3003

224. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Zarour HM, Kefford R, Loboda A, Albright A, Kang SP, Ebbinghaus S, Yearley J, Murphy E, Nebozhyn M, Lunceford JK, McClanahan T, Ayers M, Daud A. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3001.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3001

225. Riedl C, Pinker K, Ong L, Jochelson MS, Ulaner G, McArthur HL, Dickler MN, Weber W. FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1051.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1051

226. Riely GJ, Yu HA, Stephens D, Pietanza MC, Smith-Marrone S, Fiore JJ, Goldstein M, Sima CS, Kris MG, Ginsberg MS. A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8064.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8064

227. Rizvi NA, Brahmer JR, Ou SI, Segal NH, Khleif S, Hwu W, Gutierrez M, Schoffski P, Hamid O, Weiss J, Lutzky J, Maio M, Nemunaitis JJ, Jaeger D, Balmanoukian AS, Rebelatto M, Steele K, Li X, Blake-Haskins JA, Antonia SJ. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8032.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8032

228. Rizvi NA, Garon EB, Leighl N, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Rangwala RA, Lubiniecki G, Zhang J, Emancipator K, Roach CM, Rutledge R, Hui R, Ahn M, Horn L, Felip E, Carcereny Costa E. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8026.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8026

229. Robert C, Joshua AM, Kefford R, Joseph RW, Wolchok JD, Hodi FS, Hamid O, Weber JS, Gangadhar TC, Dronca RS, Patnaik A, Zarour HM, Hwu W, Hersey P, Daud A, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Ribas A. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9050.

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9050

230. Rosenblat TL, Jurcic JG, Heaney ML, Raza A, Mears JG, Santos R, Carrillo D, Gonzales J, Harwood K, Santos M, Zhang R, Ibanez G, Hogdal L, Crombie JL, Djaballah H, Scandura JM, Letai AG, Frattini MG. A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in

patients with advanced myeloid malignancies. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e18025. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e18025

231. Ross DS, Zehir A, Cheng DT, Nafa K, Jour G, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 604. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/604

232. Ruppert LM, Scher HI. Skeletal morbidities in the prostate cancer (PC) patient. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16106. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16106

233. Samoila A, Patel C, Kothadia KJ, You D, Lemetre C, Scacalossi DM, Babady NE, Peerschke EIB. Method development and validation for clinical cfDNA extraction from blood. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e22185. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22185

234. Sampson JH, Vlahovic G, Sahebjam S, Omuro AMP, Baehring JM, Hafler DA, Voloschin AD, Paliwal P, Grosso J, Coric V, Cloughesy TF, Lim M, Reardon DA. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3010. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3010

235. Sartor AO, Fernandez DC, Morris MJ, Iagaru A, Brown A, Almeida F, Sweeney C, Smith MR, Dicker A, Wong Y, Shore ND, Gratt J, Petrenciuc O, Germino J, Vogelzang NJ. Ra-223 experience in pretreated patients: EAP setting. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5063. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5063

236. Sauter CS, Riviere I, Bernal Y, Wang X, Purdon T, Yoo S, Moskowitz CH, Giralto S, Matasar MJ, Curran KJ, Park JH, Sadelain M, Brentjens RJ. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-hodgkin lymphoma (B-NHL). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8515. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8515

237. Schapiro M, Hayashi RJ, Liu W, Srivastava DK, Jeffe D, Perkins SM, Armstrong GT, Robison LL, Stovall M, Leisenring WM, Krull KR. Neurocognitive, emotional, and quality of life outcomes in long-term survivors of rhabdomyosarcoma: A report from the childhood cancer survivor study (CCSS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10072. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10072

238. Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ. The prostate cancer working group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5000. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5000

239. Schiller GJ, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Erba HP, Pigneux A, Horst H, Recher C, Klimek VM, Odenike O, Craig AR, Ward R, Smith J, Kantarjian HM, Stuart RK, Ravandi F, VALOR Investigators Group. Allogeneic hematopoietic cell transplant (HCT) in patients (pts) $\geq$ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7055. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7055

240. Schrader KA, Cheng DT, Vijai J, Prasad M, Walsh M, Zehir A, Thomas T, Benayed R, Stadler ZK, Ashraf A, Arcila ME, Solit DB, Hyman DM, Zhang L, Klimstra D, Ladanyi M, Offit K, Berger MF, Robson ME. Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1509. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1509

241. Segal NH, Ou SI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schoffski P, Antonia SJ, Massard C, Zandberg DP, Khleif S, Li X, Rebelatto M, Steele K, Robbins PB, Blake-Haskins JA, Butler MO. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3011. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3011

242. Seidman AD, Pilewskie ML, Robson ME, Kelvin JF, Zauderer MG, Epstein AS, Kris MG, Fu J, Keesing J, Caroline A, Megerian M, Eggebraaten T, DeLima R, Setnes M, Barker K, Gucalp A. Integration of multi-modality treatment planning for early stage breast cancer (BC) into watson for oncology, a decision support system: Seeing the forest and the trees. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e12042. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12042

243. Sequist LV, Goldman JW, Wakelee HA, Camidge DR, Yu HA, Varga A, Solomon B, Oxnard GR, Ou SI, Papadimitrakopoulou V, Chao BH, Liu SV, Reckamp KL, Spira AI, Piotrowska Z, Despain D, Karlovich CA, Yurasov S, Soria J. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8001. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8001

244. Shah PD, Chandarlapaty S, Dickler MN, Ulaner G, Zamora SJ, Sterlin V, Iasonos A, Coughlin CM, Morozov A, Ero J, Rosen N, Gilewski T, Fournier MN, Sklarin NT, Berger MF, Moynahan ME, Hudis CA, Baselga J, Modi S. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 590. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/590

245. Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 519. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/519

246. Shahrokni A, Temple LKF, Mahmoudzadeh S, Wills J, Sepkowitz K, Martin S. Recent and remote 30-day readmissions among cancer patients: Prevalence and association with overall survival. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e17716. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e17716

247. Sharma M, Gray E, Mehrotra S, Wu K, Barry WT, Hudis CA, Winer EP, Lyss AP, Toppmeyer D, Moreno-Aspitia A, Rugo HS, Ratain MJ, Gobburu J. A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1041. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1041

248. Sherman EJ, Ho AL, Fury MG, Baxi SS, Dunn L, Lee JS, Lipson BL, Pfister DG. Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6069. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6069

249. Sherman SI, Pagan M, Huang J, Lin B, Diggans J, Tom E, Haugen B, Tuttle RM, Kennedy G. Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 6044. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6044

250. Shih JC, Chourasia P, Gralla RJ, Msaouel P, Sidlow R, Hollen PJ. Establishing a new quality of life (QL) / patient reported outcome (PRO) / symptom scale in advanced cancer: Content validity for the "CSS" based on input from 3860 patients. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9623. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9623
251. Shoushtari AN, Postow MA, Horvat TZ, Adel NG, Dang T, Chapman PB. Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e20023. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20023
252. Shu CA, Iyengar NM, Giri DD, Chiang S, Williams S, Konner JA, Aghajanian C, Hudis CA, Dannenberg A, Makker V. Pilot study evaluating presence of crown-like structures in high grade endometrial carcinoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16504. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16504
253. Shu CA, Pike MC, Jotwani AR, Friebe TM, Soslow RA, Levine DA, Robson ME, Konner JA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Aghajanian C, Offit K, Domchek SM, Rebbeck TR, Kauff ND. Uterine cancer (ut ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1504. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1504
254. Siu LL, Papadopoulos KP, Tsai FY, Hansen AR, Robbins PB, Li X, Lai DW, Blake-Haskins JA, Fury MG. Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS3090. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS3090
255. Smyth LM, Iyengar NM, Chandarlapaty S, Sugarman S, Comen EA, Drullinsky P, Sklarin NT, Traina TA, Troso-Sandoval TA, Patil S, Wasserheit-Lieblich C, Argolo, Daniel Fontes Santos De Teive E., Baselga J, Norton L, Hudis CA, Dang CT. Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 607. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/607
256. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Mullane SA, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Ko Y, Rozzi A, Matsumoto K, Lee J, Kitamura H, Kume H, Milowsky MI, Choueiri TK, Bellmunt J. Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4527. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4527
257. Soumerai T, Hyman DM, Murali R, Zehir A, O'Cearbhaill RE, Arcila ME, Aghajanian C, Soslow RA, Solit DB, Hensley ML. Identifying actionable mutations in uterine leiomyosarcoma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5586. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5586
258. Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C, Kowanzet M, Sandler A, Funke RP, Rizvi NA. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8028. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8028
259. Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, West HJ, Eberhardt WEE, Baas P, Antonia SJ, Pluzanski A, Vokes EE, Holgado E, Waterhouse DM, Ready N, Gainor JF, Aren OR, Horn L, Paz-Ares L, Baudalet C, Lestini BJ, Brahmer JR. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-

programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8009. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8009

260. Sweeney C, Sartor AO, Vogelzang NJ, Shore ND, Cislo P, Bangerter K, Morris MJ. Effect of radium-223 dichloride (ra-223) on pain from US EAP. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e16086. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16086

261. Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot OL, Taillandier L, Tanguy M, Omuro AMP, Hoang-Xuan K. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2035. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2035

262. Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I, O'Hare TJ, Hu S, Rivera VM, Clackson TP, Conlan MG, Haluska FG, Druker BJ, Deininger MWN, Mauro MJ. Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7047. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7047

263. Tan DS, Seto T, Leighl NB, Riely GJ, Sequist LV, Felip E, Wolf J, Yang JC, Matushansky I, Yu X, Schmitz SH, Cui X, Kim D. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8013. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8013

264. Tap WD, Jones RL, Chmielowski B, Elias AD, Adkins D, Van Tine BA, Agulnik M, Cooney MM, Livingston MB, Pennock GK, Qin A, Shahir A, Ilaria RL, Conti I, Cosaert J, Schwartz GK. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (dox), in advanced soft tissue sarcoma (STS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10501. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10501

265. Tempero MA, Cardin DB, Biankin A, Goldstein D, Moore M, O'Reilly EM, Philip PA, Riess H, Macarulla T, Yung L, Li M, Lu B. Nab-paclitaxel (nab-P) plus gemcitabine (gem) vs gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4153. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4153

266. Thaker PH, Brady WE, Lankes HA, Cohn DE, Aghajanian C, Mutch DG, Mannel RS, Bell-McGuinn KM, DiSilvestro P, Jelovac D, Carter JS, Salani R. A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 5600. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5600

267. Thomas AA, Beal K, McNeill KA, Kaley TJ, DeAngelis LM, Mellinghoff IK, Diamond EL, Chan TA, Young RJ, Arevalo Perez J, Yamada Y, Anderson BD, Lamson M, Burch B, Karmali RA, Omuro AMP. Phase IB trial of carboxamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2062. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2062

268. Thompson JA, Motzer R, Molina AM, Choueiri TK, Heath EI, Kollmannsberger CK, Redman BG, Sangha RS, Ernst DS, Pili R, Butturini A, Wiseman A, Trave F, Anand B, Huang Y, Reyno LM. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas

(RRCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2503.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2503

269. Tolaney SM, Beeram M, Beck JT, Conlin AK, Dees EC, Dickler MN, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Turner PK, Cai N, Chan EM, Pant S, Becerra C, Kalinsky K, Puhalla S, Rexer BN, Burris HA, Goetz MP. A phase Ib study of abemaciclib with therapies for metastatic breast cancer. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 522.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/522

270. Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett TM, Bargou RC, Holland C, Benjamin J, Litzow MR. Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 7051.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7051

271. Traina TA, Miller K, Yardley DA, O'Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME, Schmid P, Gianni L, Garcia-Estevez L, Nanda R, Ademuyiwa FO, Chan S, Steinberg JL, Blaney ME, Tudor IC, Uppal H, Peterson AC, Hudis CA. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 1003.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1003

272. Turner NC, Balmana J, Fasching PA, Hurvitz SA, Telli ML, Visco F, Wardley AM, Zhang C, Lokker NA, Lounsbury DL, Robson ME. A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS1108.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS1108

273. Varghese AM, Hyman DM, Zehir A, Vakiani E, Klimstra DS, Ladanyi M, Berger MF, Solit DB, Saltz L. Prospective identification of potentially actionable molecular alterations in cancers of unknown primary. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4110.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4110

274. Venkatramani R, Anderson JR, Million L, Coffin CM, McCarville B, Randall RL, Parham D, Kao SC, Hayes-Jordan AA, Wolden SL, Terezakis SA, Black JO, Laurie F, Speights RA, Skapek S, Hawkins DS, Spunt SL. Risk-based treatment for synovial sarcoma in patients under 30 years of age: Children's oncology group study ARST0332. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10012.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10012

275. Voss MH, Chen Y, Chaim J, Coskey DT, Woo K, Redzematovic A, Wang P, Lee W, Patil S, Molina AM, Hsieh J, Motzer R, Feldman DR. A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4522.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4522

276. Voss MH, Coates A, Garmey EG, Haas NB, Hutson T, Keefe SM, Motzer R, Piscitelli A, Vogelzang NJ, Figlin RA. Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4579.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4579

277. Voss MH, Plimack ER, Rini BI, Atkins MB, Alter R, Bhatt RS, Beck JT, Mutyaba M, Pappas KM, Wilson D, Zhang X, Sherman ML, Pandya SS. The DART study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS4583.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4583

278. Voss MH, Plimack ER, Rini BI, Atkins MB, Alter R, Bhatt RS, Beck JT, Mutyaba M, Pappas KM, Wilson D, Zhang X, Sherman ML, Pandya SS. The DART study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 4567. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4567
279. Walewski JA, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen AI, Stiff PJ, Viviani S, Bachanova V, Sweetenham JW, Lee S, Huebner D, Larsen EK, Hunder NNH, Moskowitz CH. Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8519. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8519
280. Wang X, Sun C, Quinones Lombrana A, Singh P, Landier W, Hageman L, Mather M, Chen L, Armenian S, Winick NJ, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S. CELF4 variant and anthracycline-related cardiomyopathy (anth-card) - A COG study (ALTE03N1). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 10066. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10066
281. Watters JW, Dickson MA, Schwartz GK, Le Cesne A, Bahleda R, Wagner AJ, Choy E, De Jonge MJ, Light M, Jung J, Lee JS, Mace S. TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2515. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2515
282. Wheeler HE, Travis LB, Budnick A, Feldman DR, Einhorn LH, Hamilton RJ, Vaughn DJ, Beard C, Fung C, Johnson E, Moore MJ, Sahasrabudhe DM, Fossa SD, Sesso HD, Dolan ME, Frisina RD, The Platinum Study Group. Comprehensive characterization of cisplatin-related hearing loss in U.S. and canadian testicular cancer survivors (TCS). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9570. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9570
283. Wiesenthal A, Dave V, Thaler HT, Glare PA. Evaluation of the MPM2 score versus clinical predictions of mortality in a tertiary cancer center. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9547. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9547
284. Wildes TM, Tew WP, Maggiore RJ, Edwards BJ, Cohen HJ, Smith DD, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Katheria V, Akiba C, Hurria A, The Cancer and Aging Research Group,. Association of geriatric assessment factors with falls in older adults initiating chemotherapy. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9542. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9542
285. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill AG, Haanen JBAG, Maio M, McArthur GA, Yang A, Rollin L, Horak CE, Larkin JMG, Hodi FS. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067). *ASCO Meeting Abstracts*. 2015 June 22; 33(18_suppl): LBA1. http://meeting.ascopubs.org/cgi/content/abstract/33/18_suppl/LBA1
286. Wolchok JD, Hamid O, Ribas A, Robert C, Kefford R, Hwu W, Weber JS, Joshua AM, Gangadhar TC, Dronca RS, Daud A, Patnaik A, Joseph RW, Zarour HM, Li XN, Xue D, Ebbinghaus S, Kang SP, Perrone AM, Hodi FS. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3000. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3000
287. Yaeger RD, Miller VA, Kelsen JR, Wang K, He Y, Sanford EM, Balasubramanian S, Tang LH, Kelsen DP. Genomic analysis of colitis-associated cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 3566. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3566

288. Yee MK, Lin Y, Gorantla VC, Butterfield LH, Kluger HM, Chapman PB, Gangadhar TC, Milhem MM, Pavlick AC, Amaravadi RK, Schuchter LM, Tarhini AA, Kirkwood JM, Tawbi HA. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): TPS9088.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9088
289. Yoo SS, Tang JY, Rogers GS, Olencki T, Lacouture ME, Kudchadkar RR, Guillen J, Mun Y, Dawson KL, Sekulic A. Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 9022. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9022
290. Yu AF, Yadav NU, Eaton A, Lung BY, Thaler HT, Liu J, Hudis CA, Dang CT, Steingart R. Cardiac safety of continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e11602.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e11602
291. Yu HA, Oxnard GR, Spira AI, Horn L, Weiss J, Feng Y, West HJ, Giaccone G, Evans TL, Kelly RJ, Fleege T, Poondru S, Jie F, Aoyama K, Foley MA, Whitcomb D, Keating AT, Krivoshik AP. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8083.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8083
292. Yu HA, Sima CS, Reales D, Jordan S, Rudin CM, Kris MG, Michor F, Pao W, Riely GJ. A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8017.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8017
293. Zabor EC, Heller G, Schwartz LH, Chapman PB. Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e20020.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20020
294. Zanna C, Vaslin A, Voss MH, Heist RS, Hierro C, Supko JG, Nakai K, Ishii N, Menetrey A, Roubaudi-Fraschini M, Cordier J, Douchain J, Nicolas-Metral V. Preliminary clinical pharmacokinetics and pharmacodynamics of debio 1347 (CH5183284), a novel FGFR inhibitor. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 2540.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2540
295. Zardavas D, Te Marvelde L, Milne R, Joensuu H, Moynahan ME, Hennessy B, Bieche I, Saal LH, Stal O, Iacopetta B, Dupont Jensen J, O'Toole S, Barbareschi M, Noguchi S, Lerma E, Wang Q, Piccart-Gebhart MJ, Sotiriou C, Michiels S, Loi S. Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC). *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 516. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/516
296. Zonder JA, Raje NS, Scott EC, Hofmeister CC, Lendvai N, Anderson LD, Hari P, Orloff GJ, Berdeja JG, Singhal S, Craig M, Valent JN, Ptaszynski M, Schreiber J, Aitchison R, Usmani SZ. A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): 8612.
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8612